BMY
Categories of dependency expected for this filer that were actually found stated in Risk Factors / MD&A.
- Filing
- 0000014272-26-000004 (10-K)
- Period
- 2025-01-01 to 2025-12-31
- XBRL tag
- us-gaap:Revenues
- Context
- c-1
- Mapping
- seed · confidence 1.00
Extracted from Risk Factors / MD&A, checked verbatim against the source text before being stored.
“The expanded utilization of the 340B program in recent years has negatively affected our revenues and profit margins.”
“The growth and consolidation of MCOs and PBMs in the U.S. has also been a major factor in the healthcare marketplace.”
“Consequently, pharmaceutical companies compete aggressively to have their products included on these formularies.”
“In many markets outside the U.S., we operate in an environment of government-mandated, cost-containment programs.”
“In most EU countries, for example, the government regulates pricing of a new product at launch often through direct price controls, international price comparisons, and/or reference pricing to the current standard of care.”
“The IRA directs (i) the federal government to “negotiate” prices for select high-cost Medicare Part D (beginning in 2026) and Part B (beginning in 2028) drugs that are more than nine years (for small-molecule drugs) or 13 years (for biologics) from their initial FDA approval”
“Further, the U.S. and other countries have recently imposed, and may continue to impose, new tariffs.”
“At the state level, multiple states have passed, are pursuing or are considering government action via legislation or regulations to change drug pricing and reimbursement”